Breast Cancer clinical trials in West Virginia

10 actively recruiting breast cancer trials at 8 sites across West Virginia.

Data from ClinicalTrials.gov · last refreshed 2026-11-09

Phase 3 Recruiting Network

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medicat…

Sponsor: SWOG Cancer Research Network

NCT ID: NCT05929768

Sites in West Virginia:

United Hospital Center — Bridgeport, West Virginia
WVUH-Berkely Medical Center — Martinsburg, West Virginia
West Virginia University Healthcare — Morgantown, West Virginia
Camden Clark Medical Center — Parkersburg, West Virginia
Princeton Community Hospital — Princeton, West Virginia

View on ClinicalTrials.gov →

Phase 3 Recruiting Academic/Other

Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

This phase III trial compares the effect of continuation of treatment with pembrolizumab (usual approach) to observation only at preventing cancer from coming back in patients with early-stage triple-negative breast cancer (TNBC) who achie…

Sponsor: Alliance for Clinical Trials in Oncology

NCT ID: NCT05812807

Sites in West Virginia:

United Hospital Center — Bridgeport, West Virginia
Edwards Comprehensive Cancer Center — Huntington, West Virginia
West Virginia University Healthcare — Morgantown, West Virginia
Camden Clark Medical Center — Parkersburg, West Virginia
Princeton Community Hospital — Princeton, West Virginia

View on ClinicalTrials.gov →

Phase 3 Recruiting Network

S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity

This trial has two cohorts of patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. All patients must be receiving trastuzumab-based treatment. Both cohorts are bei…

Sponsor: SWOG Cancer Research Network

NCT ID: NCT03418961

Sites in West Virginia:

WVUH-Berkely Medical Center — Martinsburg, West Virginia
West Virginia University Healthcare — Morgantown, West Virginia
Camden Clark Medical Center — Parkersburg, West Virginia
Wheeling Hospital/Schiffler Cancer Center — Wheeling, West Virginia

View on ClinicalTrials.gov →

Phase 3 Recruiting Industry

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC) which inc…

Sponsor: Gilead Sciences

NCT ID: NCT05633654

Sites in West Virginia:

West Virginia University Hospital — Morgantown, West Virginia

View on ClinicalTrials.gov →

Phase 2 Recruiting Industry

A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with BRAF altered (BRAF V600E or BRAF fusions) locally advanced or metastatic solid tumors, or recurrent or progressive primary ce…

Sponsor: Fore Biotherapeutics

NCT ID: NCT05503797

Sites in West Virginia:

West Virginia University Health Sciences Campus — Morgantown, West Virginia

View on ClinicalTrials.gov →

Phase 2 Recruiting Industry

A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC) and Type 2 Diabetes

This study will evaluate the safety of inavolisib in combination with fulvestrant, with or without palbociclib, in participants with PIK3CA-mutated, HR+, HER2-negative ABC and type 2 diabetes.

Sponsor: Hoffmann-La Roche

NCT ID: NCT07748208

Sites in West Virginia:

West Virginia University — Morgantown, West Virginia

View on ClinicalTrials.gov →

Recruiting Academic/Other

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…

Sponsor: Alliance for Clinical Trials in Oncology

NCT ID: NCT05334069

Sites in West Virginia:

Edwards Comprehensive Cancer Center — Huntington, West Virginia

View on ClinicalTrials.gov →

Recruiting Academic/Other

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

This is a multi-site clinical study enrolling 2000 newly diagnosed patients with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer, who are planning to receive one or more systemic cancer directed therapies …

Sponsor: Wake Forest University Health Sciences

NCT ID: NCT06418204

Sites in West Virginia:

Edwards Comprehensive Cancer Center — Huntington, West Virginia

View on ClinicalTrials.gov →

Recruiting Industry

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…

Sponsor: Massive Bio, Inc.

NCT ID: NCT03452774

Sites in West Virginia:

Massive Bio SYNERGY-AI site — Morgantown, West Virginia

View on ClinicalTrials.gov →

Phase 4 Recruiting Industry

An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer.

This is a multicenter, open-label, single-arm study of prophylaxis for Dato-DXd-related stomatitis in eligible patients with metastatic or inoperable locally recurrent breast cancer or locally advanced or metastatic Epidermal Growth Factor…

Sponsor: AstraZeneca

NCT ID: NCT07357597

Sites in West Virginia:

Research Site — Charleston, West Virginia
Research Site — Morgantown, West Virginia

View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-11-09